Novo Nordisk’s new weight loss treatment inferior to tirzepatide
Novo Nordisk’s latest weight loss treatment, CagriSema, did not meet the primary endpoint of showing non-inferiority compared to…
Novo Nordisk’s CagriSema study shows 20 percent weight loss, but doesn’t beat tirzepatide
Novo Nordisk today announced headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE…